Salemonline Journal

Major Depressive Disorder Market Size in the 7MM was approximately USD 5,600 million in 2021

 Breaking News
  • No posts were found

Major Depressive Disorder Market Size in the 7MM was approximately USD 5,600 million in 2021

February 27
09:44 2023
Major Depressive Disorder Market Size in the 7MM was approximately USD 5,600 million in 2021

The major depressive disorder market report provides current treatment practices, Major Depressive Disorder emerging drugs, Major Depressive Disorder market share of individual therapies, and current and forecasted major depressive disorder market size from 2019 to 2032, segmented by seven major markets. The report also covers the current major depressive disorder treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

 

“Amongst all therapies, AXS-05 and Spravato are expected to have blockbuster potential and shall account for the highest revenue in the Major depressive disorder market over the coming years”

 

Key takeaways from the Major Depressive Disorder Market Report

 

  • The total 12-month prevalent patient population of major depressive disorder in the 7MM countries was over 48 million cases in 2021.

 

  • As per DelveInsight’s estimate, the total Major Depressive Disorder prevalent cases in 2020 were reported to be 43,845,330 in the 7MM.

 

  • The major depressive disorder market size in the seven major markets was approximately USD 5,600 million in 2021.

 

  • The leading Major Depressive Disorder Companies include Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, AbbVie, Janssen Research & Development, Axsome Therapeutics, AbbVie Luye Pharma, Relmada Therapeutics, GH Research) Praxis Precision Medicines, XWPharma, Clexio Biosciences Ltd, VistaGen Therapeutics, Alector(NASDAQ: ALEC), Chase Therapeutics, Minerva Neurosciences, and many others.

 

  • Promising Major Depressive Disorder Pipeline Therapies includes AXS-05, LY-03005, MIN-202, SAGE-217, REL-1017, CAPLYTA, PRAX 114, GH001, NBI-1065845, PH 10A, XW 10508 RP-5063, Zelquistinel, Apimostinel, SP-624, SLS-002, CTC-501 CLE-100, AV 101, OPC-64005, PDC 1421, NBI-1065845, MM-120, Zuranolone, AL001, SPL026, CTC-413, CYB003, GH001, and many others.

 

Discover which therapies are expected to grab the Major Depressive Disorder market share @ Major Depressive Disorder Market Research Report

 

Recent Breakthroughs in the Major Depressive Disorder Market

 

  • In August 2022, Relmada Therapeutics (NASDAQ: RLMD) announced that FDA granted Fast Track designation to REL-1017 (esmethadone) as a monotherapy for the treatment of MDD.

 

  • In June 2022, Cybin received FDA IND clearance for its Phase I/IIa clinical trial evaluating CYB003 for the potential treatment of Major Depressive Disorder.

 

  • In June 2022,  Biogen(NASDAQ: BIIB) and Sage Therapeutics(NASDAQ: SAGE) announced that the Phase III SKYLARK Study of zuranolone, an investigational oral drug was being evaluated in women with postpartum depression (PPD), met its primary and all key secondary endpoints. Women treated with zuranolone 50 mg (n=98) demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, compared to placebo (n=97) as measured by a change from baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAMD-17) total score.

 

  • In October 2021, Small Pharma (CVE: DMT) granted Fast-Track Designation from the UK regulator for SPL026 DMT-Assisted therapy for Major Depressive Disorder.

 

  • In October 2021, Chase Therapeutics announced $20 million Series B financing to advance clinical trials in Parkinson’s disease and Major Depressive Disorder. The proceeds of Series B will support Phase 3 pivotal trials for CTC-501 for the treatment of Major Depressive Disorder (MDD) and CTC-413 for the treatment of Parkinson’s disease (PD) as well as completion of the development and validation of a diagnostic product for Parkinson’s disease.

 

Major Depressive Disorder Overview

Major depressive disorder (MDD), also referred to as depression, is a serious medical illness that disrupts a person’s mood, behavior, and thought processes, apart from degrading physical health. It should not be mistaken for the passing feelings of unhappiness that everyone experiences, nor should it be confused with the intense grief brought about by the death of a loved one. Sadness and grief are normal reactions to life stresses. With time, and usually, without medical treatment, sadness and grief lift, and people go on with their lives. By contrast, without specialized medical treatment, depression often persists.

 

Major Depressive Disorder Epidemiological Segmentation in the 7MM

  • Prevalent Cases of Major Depressive Disorder prevalent cases
  • Gender-specific Major Depressive Disorder Prevalent Cases
  • Severity-specific Major Depressive Disorder Prevalent Cases
  • Major Depressive Disorder Cases Relapsed/Refractory

 

Download the report to understand which factors are driving Major Depressive Disorder epidemiology trends @ Major Depressive Disorder Epidemiological Insights

 

Major Depressive Disorder Market Outlook

The available first-line pharmacotherapy options include selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs) Second-line pharmacotherapy options include monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs). Concomitant medication with the use of other antidepressants or antipsychotics is common in treated patients.

 

Major Depressive Disorder Treatment Market

The Major Depressive Disorder treatment market is segmented based on various phases like the acute phase, continuation phase, and maintenance phase of treatment; however, different types of depression require different treatments. Currently, most MDD patients are treated with pharmacotherapy, psychotherapy, or a combination of both.

 

Major Depressive Disorder Pipeline Therapies and Companies

  • Travivo: Fabre-Kramer Pharmaceuticals
  • Vraylar: Allergan/Gedeon Richter
  • PDC-1421: Biolite Inc.
  • AV-101: VistaGen Therapeutics
  • AXS-05: Axsome Therapeutics
  • Pramipexole (CTC-501): Chase Therapeutics
  • SAGE-217: Sage Therapeutics
  • LY03005: Luye Pharma Group
  • Seltorexant: Minerva Therapeutics
  • PH10: VistaGen Therapeutics
  • PRAX-114: Praxis Precision Medicines
  • REL-1017: Relmada Therapeutics
  • Caplyta: Intra-Cellular Therapies

 

Learn more about the FDA-approved drugs for Major Depressive Disorder treatment @ Drugs for Major Depressive Disorder Treatment

 

Major Depressive Disorder Market Dynamics

The Major Depressive Disorder size growth is anticipated to surge owing to an increasing awareness that shall lead to accurate diagnosis, therefore, timely treatment in primary care settings using antidepressant medications and/or brief structured psychological therapies. However, the growth is expected to be hindered by substantial barriers such as supply-side factors (for example, policies to invest resources, and consequent scarce mental health services, community and human resources), as well as demand-side issues (for example, lack of awareness of MDD as a treatable illness, and stigma and social exclusion associated with lower rates of help-seeking).

 

Major depressive disorder Emerging Drugs

 

  • Several companies are working robustly on many new therapies, such as AXS-05 (Axsome Therapeutics), Vraylar (AbbVie), Zuranolone (SAGE Therapeutics), and LY03005 (Luye Pharma). The mid-stage pipeline is crowded, with several potential therapies with the imminent attention of big pharmaceutical companies for this market space.

 

  • AXS-05 (Axsome Therapeutics), is a novel, oral, patent-protected, investigational NMDA receptor antagonist with multimodal activity under development to treat major depressive disorder and other central nervous systems (CNS) disorders. AXS-05 utilizes a proprietary formulation and dose of dextromethorphan and bupropion and Axsome’s metabolic inhibition technology to modulate the delivery of the components. The dextromethorphan component of AXS-05 is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, also known as a glutamate receptor modulator, which is a novel mechanism of action, meaning it works differently than currently approved therapies for major depressive disorder. The dextromethorphan component of AXS-05 is also a sigma-1 receptor agonist. The bupropion component of AXS-05 serves to increase the bioavailability of dextromethorphan and is a norepinephrine and dopamine reuptake inhibitor.

 

  • Vraylar (AbbVie) is an oral, once-daily atypical antipsychotic approved for the acute treatment of adult patients with manic or mixed episodes associated with bipolar I disorder, with a recommended dose range of 3–6 mg/day, and for the treatment of schizophrenia in adults, with a recommended dose range of 1.5–6 mg/day. 

 

Scope of the Major Depressive Disorder Market Report

 

  • Coverage- 7MM

 

  • Major Depressive Disorder Companies- Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, AbbVie, Janssen Research & Development, Axsome Therapeutics, AbbVie Luye Pharma, Relmada Theraputics, GH Research) Praxis Precision Medicines, XWPharma, Clexio Biosciences Ltd, VistaGen Therapeutics, Alector(NASDAQ: ALEC), Chase Therapeutics, Minerva Neurosciences, and many others.

 

  • Major Depressive Disorder Pipeline Therapies includes AXS-05, LY-03005, MIN-202, SAGE-217, REL-1017, CAPLYTA, PRAX 114, GH001, NBI-1065845, PH 10A, XW 10508 RP-5063, Zelquistinel, Apimostinel, SP-624, SLS-002, CTC-501 CLE-100, AV 101, OPC-64005, PDC 1421, NBI-1065845, MM-120, Zuranolone, AL001, SPL026, CTC-413, CYB003, GH001, and many others.

 

  • Major Depressive Disorder Market Dynamics: Major Depressive Disorder Market Drivers and Barriers

 

Discover more about drugs for multiple system atrophy in development @ Major Depressive Disorder Ongoing Clinical Trials Analysis

 

Table of Content

1. Key Insights

2. Report Introduction

3. Major Depressive Disorder Market Overview at a Glance

4. Executive Summary of Major Depressive Disorder

5. Disease Background and Overview

6. Epidemiology and Patient Population

7. Treatment and Management

8. Organizations contributing towards MDD

9. Patient Journey

10. Case Report

11. Marketed Therapies

12. Emerging Therapies

13. Other Assets

14. Discontinued Therapies

15. Major Depressive Disorder (MDD): 7 Major Market Analysis

16. SWOT Analysis

17. Unmet Needs

18. Market Access

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

 

To know more about Major Depressive Disorder Treatment Options, visit Major Depressive Disorder Treatment Drugs

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Related Articles